Assess the risk of cancer in just a few minutes!
Screening of lumps and bumps in dogs.
Using Heat Diffusion Imaging (HDI) technology and an Artificial Intelligence algorithm, cancer in subcutaneous and dermal masses can be ruled out in a matter of minutes.
Diagnosis of common tumor types:
In all cases where HT Vista detects a low or high probability of malignancy, benign tumors such as lipomas or malignant tumors such as mast cell tumors can be diagnosed. This avoids unnecessary invasive procedures for lipomas and enables mast cell tumors to be detected at an early stage.
Cancer screening with HT Vista®
Cancer is the most common cause of death in dogs.
1/3 of tumors are located on or under the skin. Unfortunately, many lumps or bumps are still not examined in detail today.
Early screening is the most important and effective step in cancer treatment.
Did you know that...
- 40% of masses are not even sampled.
- 20% of cytology samples are non-diagnostic.
- 30% of dogs have more than one mass.
- Many samples need external laboratory.
- More than 80% from 1'000 masses of the study findings with HT Vista were not malignant.
Cancer risk assessment
HT Vista® is an innovative system that uses patented and validated imaging technology and Artificial Intelligence to simplify the examination of lumps and bumps.
With this non-invasive system, dermal and subcutaneous skin tumors can be examined on site in just a few minutes to reliably rule out cancer and obtain a diagnosis with a sensitivity of 90%!
Cancer detection with screening and diagnostic function
Advances in artificial intelligence and the steadily growing number of validated masses, now numbering almost 1,200, have enabled the programming of two new functions in screening:
Assessment of cancer risk in three stages: The visual representation of cancer risk in three stages supports rapid assessment of lumps and bumps immediately after examination.
It assists in decision-making by identifying low-risk cases that can be safely monitored and recommending next steps for medium- and high-risk cases.
Screening results are based on a Sensitivity (Sen) of 90% and a Negative Predictive Value (NPV) of 98%.
The cancer risk is presented based on the probability of malignancy.
Low risk: Malignant Probability ≤10%
Moderate Cancer Risk- Malignant Probability 11%-49%
High Cancer Risk- Malignant Probability ≥50%
AI-supported tumor subclassification:
Following the assessment of cancer risk, benign tumors such as lipomasand malignant tumors such as mast cell tumors (MCTs) are diagnosed.
In all cases where HT Vista determines a very low or very high probability of malignancy, a diagnosis of the tumor type is made using a specifity of at least 90% . This avoids unnecessary invasive procedures for benign lipomas and enables early detection of MCTs.
Read the full article -> HT Vista 4.0: Introducing HT Vista's New Diagnostic Capability
Advantages of cancer screening with HT Vista
Direct at your point of care
Examination and results on site.
Non-invasive
A stress, and risk free experience for patient and owner.
Affordable
Cost-effective screening with rapid return on investment.
Result in 5-10 minutes
With Artificial Intelligence generated result.
98% Negative Predictive Value (NPV) in avg.
90% sensitivity
Easy to use
Suitable for all your technical staff.
Unique new technology
HT Vista® from HTVet is the first AI-driven non-invasive screening tool that enables veterinarians and their specialist staff to evaluate the cancer risk in subcutaneous and dermal masses using heat diffusion imaging (HDI) and artificial intelligence, and to obtain diagnoses.
This innovative patented imaging modality relies on unique thermal signals that differ between normal and malignant tissues, as they are recorded by the device.
Using artificial intelligence, the algorithm compares the patient's signal with previously learned signals and calculates the probability of malignancy.
The algorithm is constantly being improved through continuous training and the validated results of almost 1’200 the algorithm is continuously being improved and new types of tumors are being diagnosed.
On the web page of HTVet you will find the latest international press releases and news.
Result in few minutes
Registration
Checking patient masses and data entry.
Preparation scan
Trimming of the affected areas.
Scanning
Scanning of affected areas and screening.
Screening and diagnosis
Analysis of cancer risk and common types of tumors.
Result in a few minutes
Evaluation of the analysis within a few minutes.
Next steps
Discussion of the result with the animal owner.
Result available 5-10 minutes after the scan!
Testimonials
We now use the device to screen every cutaneous or subcutaneous lump that we see in our canine patients prior to obtaining an aspirate. We have seen the greatest impact in patients with multiple, long-standing skin masses where owners can be reluctant to aspirate or biopsy multiple lesions and are more concerned about the risk of GA or sedation. The non-invasive nature of the HT Vista is much more appealing to pet owners and gives a quick result within minutes! In addition, the algorithm and AI is constantly evolving and learning from the samples that are taken and so I am confident the scanner will offer more features in the future!"
Development and manufacturing
HT Vista was developed together with veterinary oncologists and specialists in innovative imaging techniques and artificial intelligence. The algorithms for analyzing cutaneous and subcutaneous masses are continuously trained and developed. The system learns with each new scan.
The system is developed and manufactured according to medical technology guidelines and is approved for veterinary medicine.
It is imported, controlled and trained by P12 Medical in Switzerland. All regulatory requirements of Switzerland and the EU are fulfilled by the system.